Market Place
Sourcing Support
All News #Library
Biotech
Psyence BioMed Starts NPX-5 Phase 2b Dosing for Adjustment
23 Apr 2026 //
GLOBENEWSWIRE
Psyence Biomed Grows Its Australian Clinical Site Network
08 Apr 2026 //
GLOBENEWSWIRE
Psyence Biomed Expands Integrated Pharma Platform Post Psylabs
11 Mar 2026 //
GLOBENEWSWIRE
Psyence BioMed Ships GMP NPX-5 for Australia Phase IIb Trial
03 Mar 2026 //
GLOBENEWSWIRE
Psyence Biomed Reveals Shareholders Meeting Outcomes
17 Feb 2026 //
GLOBENEWSWIRE
Psyence Biomed Approves Put Option Agreement With Psylabs
13 Feb 2026 //
GLOBENEWSWIRE
Psyence Biomed Board Approves 2026 Strategy, Buyback
12 Jan 2026 //
GLOBENEWSWIRE
Psyence Biomed Advances Ibogaine Hcl Production, Boosts Balance
05 Jan 2026 //
GLOBENEWSWIRE
Psyence BioMed Launches Phase IIb Psilocybin Trial
19 Dec 2025 //
GLOBENEWSWIRE
Psyence Biomed Launches Psilocybin Longevity Research Program
25 Nov 2025 //
GLOBENEWSWIRE
Psyence Biomed Achieves Key Ibogaine Supply Breakthrough
20 Nov 2025 //
GLOBENEWSWIRE
Psyence BioMed Launches Ibogaine Ops in South Africa
12 Nov 2025 //
GLOBENEWSWIRE
Corporate Update, August 2025
04 Aug 2025 //
GLOBENEWSWIRE
Psyence Biomed Signs Binding Agreements with Optimi Health Corp
10 Dec 2024 //
GLOBENEWSWIRE
Psyence Biomed Adds Second Site For Psilocybin Trial
24 Oct 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.